EVALUATE DIAGNOSTIC ACCURACY OF NKX3.1 WITH AMACR & P63 IN PROSTATIC ADENOCARCINOMA
Main Article Content
Keywords
NKX3.1, AMACR, P63, prostatic adenocarcinoma, cancer, immunohistochemistry, tumour, diagnosis
Abstract
The most prevalent type of cancer in males is prostate adenocarcinoma. Based only on histologic features, it can occasionally be challenging to distinguish prostatic adenocarcinoma from prostatic mimickers. Using immunohistochemistry (IHC) and a negative immunological response to p63, along with positive staining for Alpha Methyl Acyl CoA Racemase (AMACR), cancer is diagnosed. The prostatic tumour suppressor gene NKX3.1 is found on chromosome 8p. While most primary prostatic adenocarcinomas stain positive for the NKX3.1 protein, most high-grade prostate cancers have it downregulated, and most metastatic prostate cancers have it completely lost (e.g., in 65% to 78% of lesions), according to most studies. Therefore, the study aimed to evaluate the diagnostic accuracy of Nkx3.1 in combination with AMACR & P63 in prostatic adenocarcinoma. This was an observational, prospective & retrospective study involving 56 samples of biopsies and specimens, conducted over a period of 12 months after the fulfillment of the criteria. After following the standard protocol for specimen staining, the IHC was carried out. The correlated histopathological features in all the cases were selected, and the diagnostic utility was determined statistically. The data was collected and analysed using the Chi-square test, all the results showed 5% level of significance & 95% confidence interval with a p-value of <0.05. The maximum age group of the patients was within 70-80 years, with the maximum cases of prostatic adenocarcinoma diagnosed in 42 (75%) patients, with 15 (26.8%) in grade 4. A high statistical significance was seen between the association of diagnosis with IHC expression. To distinguish between adenocarcinoma and its mimics of prostatic lesions, NKX3.1 as a diagnostic performance in a combination with p63 and AMACR proves to be significant. In suspected situations, IHC is advised to minimise diagnostic error.
References
2. Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018 Nov;12(6):1807-1823.
3. Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol. 2017 Apr;4(2):86-95.
4. Cho JM, Lee SW, Kang JY, Yoo TK. Safety and efficacy of combined transrectal ultrasound-guided prostate needle biopsy and transurethral resection of the prostate. Korean J Urol. 2010 Feb;51(2):101-5.
5. Hasan IA, Gaidan HA, Al-Kaabi MM. Diagnostic Value of Cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions. Iran J Pathol. 2020 Summer;15(3):232-238
6. Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, Petrovics G, Cullen J, Mcleod DG, Rosner IL, Srivastava S, Sesterhenn IA. Prognostic features of Annexin A2 expression in prostate cancer. Pathology. 2021 Feb;53(2):205-213.
7. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005 Feb;123(2):231-6.
8. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005 Jul;47(1):1-16.
9. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol. 2004 Mar;17(3):328-48.
10. Mahapatra QS, Mohanty P, Nanda A, Mohanty L. Histomorphological study of prostatic adenocarcinoma and its mimics. Indian J Pathol Microbiol. 2019 Apr-Jun;62(2):251-260.
11. Rathod SG, Jaiswal DG, Bindu RS. Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm. J Family Med Prim Care. 2019 Aug 28;8(8):2651-2655.
12. Kalantari MR, Anvari K, Jabbari H, Tabrizi FV. p63 is more sensitive and specific than 34βE12 to differentiate adenocarcinoma of prostate from cancer mimickers. Iran J Basic Med Sci. 2014 Jul;17(7):497-501.
13. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004 Dec;35(12):1462-8.
14. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol. 2007 Jan;60(1):35-42.
15. Patel ZM, Doshi PR, Lakhe RR, Shelke. Utility of P63 and Alpha Methyl Acyl Co A Racemase in the Lesions of Prostatic Minickers: An observational Study, J Clin of Diagn Res, 2023:17(2), EC36-EC39.
16. Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation. 2008 Jul;76(6):717-27.
17. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res. 2006 Nov 15;66(22):10683-90.
18. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol. 2002 Mar;22(5):1495-503.
19. Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, Vocke CD, Linehan WM, Ferretti JA. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol. 2001 Apr;165(4):1329-34.
20. Malik N, Maheshwari V, Aijaz M, Afroz N (2022) Diagnostic significance of combined immunohistochemical panel of p63, High Molecular Weight Cytokeratin (34betaE12) and α Methyl Acyl Co A Racemase (AMACR) in resolving suspicious foci in prostatic lesions. Ann Cytol Pathol 7(1): 029-034.
21. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002 Apr 15;62(8):2220-6.
22. Ng VW, Koh M, Tan SY, Tan PH. Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. Am J Clin Pathol. 2007 Feb;127(2):248-53.
23. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002 Sep;26(9):1161-8.
24. Singh V, Manu V, Malik A, Dutta V, Mani NS, Patrikar S. Diagnostic utility of p63 and α-methyl acyl Co A racemase in resolving suspicious foci in prostatic needle biopsy and transurethral resection of prostate specimens. J Cancer Res Ther. 2014 Jul-Sep;10(3):686-92.
25. Sadeghifar, M., Madani, S., Khazaei, S., Izadi, B., Kanani, M., & Roozbahani, N. (2021). Evaluation of the diagnostic value of immunohistochemistry staining for P63, Alpha-methyl Acyl-CoA Racemase, CK5/6, and 34βE12 in prostate carcinoma. Clinical Cancer Investigation Journal, 10(4), 214-218.
26. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000 Nov 1;60(21):6111-5.
27. Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Danielsen H, Kung J, Sellers WR, Loda M, Saatcioglu F. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol. 2004 Sep;172(3):1134-9.
28. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate. 2003 May 1;55(2):111-7.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Ekta Bhushan
Post-graduate resident, Department of Pathology, Bharati Vidyapeeth Deemed University Medical College Hospital and Research Centre, Pune, Maharashtra, India
Dr R.C. Nimbargi
Professor, Department of Pathology, Bharati Vidyapeeth Deemed University Medical College Hospital and Research Centre, Pune, Maharashtra, India
Dr Priyanka Yadav
Post-graduate resident, Department of Pathology, Bharati Vidyapeeth Deemed University Medical College Hospital and Research Centre, Pune, Maharashtra, India
Dr Reena Bharadwaj
Professor and Head, Department of Pathology, Bharati Vidyapeeth Deemed University Medical College Hospital and Research Centre, Pune, Maharashtra, India